How pharma is learning to talk—and listen
In today’s communication-driven world, where every interaction matters, the pharma industry is embracing conversations that build…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Dr Reddy’s Laboratories
Bio-Thera, Dr. Reddy’s partner to commercialise BAT2206, a proposed Stelara Biosimilar, and BAT2506,…
Under the agreement, Bio-Thera will develop, manufacture, and supply BAT2206 and BAT2506. Dr. Reddy’s will seek regulatory…
Senores Pharma acquires 14 ANDAs from Dr. Reddy’s
The basket acquired comprises 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
USFDA classifies inspection at Dr Reddy’s API facility as Voluntary Action Indicated
Dr Reddy’s Laboratories receives Establishment Inspection Report for its API manufacturing facility in Bollaram, Hyderabad
Indian pharma companies focus on innovative research in foreign countries through dedicated entities
According to GlobalData’s Pharmaceutical Intelligence Center, as of 20 December 2024, there are a total of 16 drugs in the…
Eco-conscious packaging: A strategic opportunity
Larger pharma companies are applying sustainable practices and eco-conscious materials to packaging and labelling, leading to…
Toripalimab can fortify Dr. Reddy’s oncology portfolio as first checkpoint inhibitor for NPC in…
Dr. Reddy's Laboratories, in collaboration with Shanghai Junshi Biosciences has recently launched checkpoint inhibitor Zytorvi…
Dr. Reddy’s launches Toripalimab under the brand name Zytorvi in India
Toripalimab is an immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
17th CPHI & PMEC India Expo to highlight advancements in pharma industry
Event to focus on innovation, sustainability, and India’s growing role in the global pharma sector
Biocon and Dr Reddy’s featured in Science Magazine’s Top Employers List
This year’s ranking is based on a comprehensive web-based survey of about 6,400 respondents